Early Awake Prone Position Combined with High-Flow Nasal Oxygen Therapy in Severe COVID-19: A Case Series

BACKGROUND: Awake prone positioning has been used for non-intubated patients with COVID-19-related acute hypoxaemic respiratory failure, but the results are contradictory. We aimed to highlight the role of awake prone positioning combined with high-flow nasal oxygen therapy in severe COVID-19 patients infected with the Delta variant of SARS-CoV-2. METHODS: From June 12 to December 7, 2021, we successfully performed prone position(PP) combined with high-flow nasal oxygen(HFNO) therapy on two patients infected with the delta variant of SARS-CoV-2. HFNO was prescribed to reach SpO(2) ≥ 92%. PP was proposed to patients with PaO(2)/FiO(2)(P/F) < 150 mmHg. Arterial blood gas (ABG) and hemodynamic were monitored before and after PP sessions. The target time of PP was more than 12 h per day and could be appropriately shortened according to the patient’s tolerance. Relevant clinical data, HFNO parameters, PICCO parameters, P/F ratio and PP duration were obtained from medical records. RESULTS: A total of 23 PP sessions and 6 PP sessions combined with HFNO were performed in case 1 and case 2, respectively. Compared with values before PP, GEDI, ELWI and Qs/Qt decreased significantly (GEDI: 869.50 ± 60.50 ml/m(2) vs. 756.86 ± 88.25 ml/m(2); ELWI: 13.64 ± 2.82 ml/kg vs. 12.43 ± 2.50 ml/kg; Qs/Qt: 15.32 ± 6.52% vs. 12.24 ± 5.39%; all p < 0.05), Meanwhile, the oxygenation improved significantly (P/F: 184.50 ± 51.92 mmHg vs. 234.21 ± 88.84 mmHg, p < 0.05), The chest CT revealed the lung infiltrates improved significantly after PP. Both cases were discharged to a dedicated COVID-19 ward without requiring intubation. CONCLUSIONS: Combining PP with HFNO could be a useful treatment strategy for avoiding intubation in severe COVID-19 patients infected with the Delta variant of SARS-CoV-2 to improve pulmonary vascular involvement, improve oxygenation and avoid intubation, but further studies are needed to validate our approach.